Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor‐induced hypercoagulability in vitro and in vivo

This publication has 26 references indexed in Scilit:

• Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levels
  Journal of Thrombosis and Haemostasis, 2013
• Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
  New England Journal of Medicine, 2013
• What did we learn from new oral anticoagulant treatment?
  Thrombosis Research, 2012
• Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials
  BMJ Open, 2012
• Dabigatran and risk of myocardial infarction
  Nature Reviews Cardiology, 2012
• Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
  Circulation, 2012
• Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction
  Journal of Internal Medicine, 2011
• Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism
  Annual Review of Medicine, 2011
• The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by α2‐macroglobulin‐thrombin
  Journal of Thrombosis and Haemostasis, 2010
• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
  The Lancet, 2003